Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HypoBar I: Delaying intestinal glucose absorption to ameliorate post-bariatric hypoglycaemia
2022-000157-87Phase 2Terminated
- Sponsor
- Copenhagen University Hospital - Hvidovre
- Start
- Jan 2022
- Modality
- Microbiome-Derived Products → Microbiome Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in hypoglycaemia comparing canagliflozin sequence, acarbose sequence and placebo sequence (3 arms). Primary endpoint: Time under level 1 hypoglycaemia. Started Jan 2022; status: terminated.
02
Drugs
canagliflozinacarbose
03
Conditions
hypoglycaemia
Beyond the preview
Go deeper on 2022-000157-87.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000157-87.